Evidence map›Paper›PMID 38575943›Full record

ArticleJournal of nanobiotechnology2024

Osteosarcoma-targeted Cu and Ce based oxide nanoplatform for NIR II fluorescence/magnetic resonance dual-mode imaging and ros cascade amplification along with immunotherapy.

Mo Cheng, Qingjie Kong, Qing Tian, Weiluo Cai, Chunmeng Wang, Minjia Yuan, Wenxing Wang, Peiyuan Wang, Wangjun Yan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Biocompatible Mesoporous Materials for Bone Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Mo ChengDepartment of Musculoskeletal Surgery of Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China.
Qingjie KongDepartment of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, P. R. China.
Qing TianDepartment of Neurology, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, 201799, P. R. China.
Weiluo CaiDepartment of Musculoskeletal Surgery of Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China.
Chunmeng WangDepartment of Musculoskeletal Surgery of Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China.
Minjia YuanDepartment of Chemistry, iChEM (Collaborative Innovation Center of Chemistry for Energy Materials), Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, State Key Laboratory of Molecular Engineering of Polymers, Laboratory of Advanced Materials, Fudan University, Shanghai, 200433, P. R. China.
Wenxing WangDepartment of Chemistry, iChEM (Collaborative Innovation Center of Chemistry for Energy Materials), Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, State Key Laboratory of Molecular Engineering of Polymers, Laboratory of Advanced Materials, Fudan University, Shanghai, 200433, P. R. China. wangwenxing@fudan.edu.cn.
Peiyuan WangKey Laboratory of Design and Assembly of Functional Nanostructures, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, 350002, P. R. China. wangpeiyuan@fjirsm.ac.cn.
Wangjun YanDepartment of Musculoskeletal Surgery of Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China. yanwj@fudan.edu.cn.
Fudan University Shanghai Cancer Center · CNFudan University · CNCollaborative Innovation Center of Chemistry for Energy Materials · CNFujian Institute of Research on the Structure of Matter · CNShanghai Jiao Tong University · CN

Funding

National Natural Science Foundation 82072972
6 · The paper itself

Abstract

backgroundAs the lethal bone tumor, osteosarcoma often frequently occurs in children and adolescents with locally destructive and high metastasis. Distinctive kinds of nanoplatform with high therapeutical effect and precise diagnosis for osteosarcoma are urgently required. Multimodal optical imaging and programmed treatment, including synergistic photothermal-chemodynamic therapy (PTT-CDT) elicits immunogenetic cell death (ICD) is a promising strategy that possesses high bio-imaging sensitivity for accurate osteosarcoma delineating as well as appreciable therapeutic efficacy with ignorable side-effects. METHODS AND

resultsIn this study, mesoporous Cu and Ce based oxide nanoplatform with Arg-Gly-Asp (RGD) anchoring is designed and successfully constructed. After loading with indocyanine green, this nanoplatform can be utilized for precisely targeting and efficaciously ablating against osteosarcoma via PTT boosted CDT and the closely following ICD stimulation both in vitro and in vivo. Besides, it provides off-peak fluorescence bio-imaging in the second window of near-infrared region (NIR II, 1000-1700 nm) and Magnetic resonance signal, serves as the dual-mode contrast agents for osteosarcoma tissue discrimination.

conclusionTumor targeted Cu&Ce based mesoporous nanoplatform permits efficient osteosarcoma suppression and dual-mode bio-imaging that opens new possibility for effectively diagnosing and inhibiting the clinical malignant osteosarcoma.

Indexed as

Bone NeoplasmsNanoparticlesNeoplasmsOsteosarcomaAdolescentCell Line, TumorChildHumansImmunotherapyMagnetic Resonance ImagingMagnetic Resonance SpectroscopyPhototherapy

Identifiers

PMID38575943
PMCPMC10993435
OpenAlexW4393929488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.